Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Whole-Body MRI in the Evaluation of Pediatric Malignancies
This study is currently recruiting participants.
Verified by Emory University, September 2005
Sponsored by: Emory University
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00228761
  Purpose

Eligible patients will have a cancer that is known to spread to other areas of the body (metastasize). This study will look at the best way to see if and where the cancer has spread (metastatic disease). The standard tests (conventional imaging tests) that are used to determine the extent and spread of these diseases may include magnetic resonance imaging (MRI), computed tomography (CT), bone scanning, gallium scanning, and/or metaiodobenzylguanidine (MIBG) scanning. The standard tests that are required will depend on the specific disease. The main purpose of this research study is to see if a new imaging test, called whole-body fast MRI, can detect disease as accurately as the standard tests. Whole-body fast MRI is a diagnostic test that uses a large magnet to take pictures of the body with rapid imaging times. Up to now, it has not been used routinely in the evaluation of children with cancer. The results of whole-body fast MRI will be compared with that of conventional imaging for detecting distant metastases.


Condition Intervention
Metastatic Cancer
Procedure: PET, MRI, CT scans

MedlinePlus related topics: CT Scans Cancer Nuclear Scans
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: Whole-Body MRI in the Evaluation of Pediatric Malignancies

Further study details as provided by Emory University:

Primary Outcome Measures:
  • compare the results of the experimental tests with the results provided by the standard diagnostic work-up

Estimated Enrollment: 35
Study Start Date: June 2004
Detailed Description:

Eligible patients will have a cancer that is known to spread to other areas of the body (metastasize). This study will look at the best way to see if and where the cancer has spread (metastatic disease). The standard tests (conventional imaging tests) that are used to determine the extent and spread of these diseases may include magnetic resonance imaging (MRI), computed tomography (CT), bone scanning, gallium scanning, and/or metaiodobenzylguanidine (MIBG) scanning. The standard tests that are required will depend on the specific disease. The main purpose of this research study is to see if a new imaging test, called whole-body fast MRI, can detect disease as accurately as the standard tests. Whole-body fast MRI is a diagnostic test that uses a large magnet to take pictures of the body with rapid imaging times. Up to now, it has not been used routinely in the evaluation of children with cancer. The results of whole-body fast MRI will be compared with that of conventional imaging for detecting distant metastases.

In addition to studying whole-body fast MRI; the study doctors would also like to look at a second imaging study called positron emissions tomography (PET). A PET scan is a specialized imaging test that uses radiation to locate areas of disease. The PET scan portion of this study is completely optional.

  Eligibility

Ages Eligible for Study:   1 Year to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

a cancer that is known to spread to other areas of the body (metastasize) -

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00228761

Contacts
Contact: Dollicia David, BS 404-785-3633 Dollicia.David@choa.org

Locations
United States, Georgia
Children's Healthcare of Atlanta Recruiting
Atlanta, Georgia, United States, 30322
Contact: JoAnn Sadowski, BS     404-785-3531     JoAnn.Sadowski@choa.org    
Principal Investigator: Brad Wyly, MD            
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Brad Wyly, MD Children's Healthcare of Atlanta
  More Information

Study ID Numbers: 336-2004
Study First Received: September 27, 2005
Last Updated: September 27, 2005
ClinicalTrials.gov Identifier: NCT00228761  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Neoplasm Metastasis

Additional relevant MeSH terms:
Neoplasms
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on February 05, 2009